Gilead Sciences (NQ:GILD)

144.12 -0.62 (-0.42%)

Delayed Quote Updated: 2:43 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

78 79 Next >

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

March 12, 2025

From Gilead Sciences, Inc.

Via Business Wire

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

March 11, 2025

From Gilead Sciences, Inc.

Via Business Wire

These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

March 11, 2025

Via MarketBeat

The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts ↗

March 11, 2025

Via Benzinga

Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗

March 10, 2025

Via Benzinga

P/E Ratio Insights for Gilead Sciences ↗

March 07, 2025

Via Benzinga

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 11, 2025

Via Benzinga

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

March 11, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...

Via StockStory

Topics Artificial Intelligence

The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI) ↗

March 11, 2025

Via The Motley Fool

Topics Artificial Intelligence

1 Value Stock with Exciting Potential and 2 to Ignore

March 10, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

March 06, 2025

Via Benzinga

Gilead Sciences Unusual Options Activity ↗

February 24, 2025

Via Benzinga

How Is The Market Feeling About Gilead Sciences? ↗

February 19, 2025

Via Benzinga

Best And Worst Performing S&P 500 Stocks Since Trump's Election Win ↗

March 07, 2025

Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar.

Via Benzinga

Topics Government Stocks

Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook. ↗

February 26, 2025

Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products.

Via Investor's Business Daily

Topics Artificial Intelligence

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

February 24, 2025

From Gilead Sciences, Inc.

Via Business Wire

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

February 23, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.

Via StockStory

16 Analysts Have This To Say About Gilead Sciences ↗

February 18, 2025

Via Benzinga

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

February 22, 2025

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

Via MarketBeat

Topics Death

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

February 20, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Present at Upcoming Investor Conferences

February 19, 2025

From Gilead Sciences, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 18, 2025

Via Benzinga

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

February 18, 2025

From Gilead Sciences, Inc.

Via Business Wire

This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

February 18, 2025

Via Benzinga

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

February 18, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Bullish Setups ↗

February 16, 2025

You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now.

Via Talk Markets

Topics Stocks / Equities

Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday ↗

February 13, 2025

Via Benzinga

Moderna (MRNA) Q4 Earnings Report Preview: What To Look For

February 13, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect.

Via StockStory

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.